162 related articles for article (PubMed ID: 23408949)
1. Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.
Noble P; Spendlove I; Harding S; Parsons T; Durrant LG
PLoS One; 2013; 8(2):e54892. PubMed ID: 23408949
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.
Chua JX; Vankemmelbeke M; McIntosh RS; Clarke PA; Moss R; Parsons T; Spendlove I; Zaitoun AM; Madhusudan S; Durrant LG
Clin Cancer Res; 2015 Jul; 21(13):2963-74. PubMed ID: 25779947
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
[TBL] [Abstract][Full Text] [Related]
4. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants.
Kitamura K; Stockert E; Garin-Chesa P; Welt S; Lloyd KO; Armour KL; Wallace TP; Harris WJ; Carr FJ; Old LJ
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12957-61. PubMed ID: 7809154
[TBL] [Abstract][Full Text] [Related]
5. Reactivities of Lewis antigen monoclonal antibodies with the lipopolysaccharides of Helicobacter pylori strains isolated from patients with gastroduodenal diseases in Japan.
Amano K; Hayashi S; Kubota T; Fujii N; Yokota S
Clin Diagn Lab Immunol; 1997 Sep; 4(5):540-4. PubMed ID: 9302202
[TBL] [Abstract][Full Text] [Related]
6. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.
Kircheis R; Halanek N; Koller I; Jost W; Schuster M; Gorr G; Hajszan K; Nechansky A
MAbs; 2012; 4(4):532-41. PubMed ID: 22665069
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.
Guo J; Jiang W; Li Q; Jaiswal M; Guo Z
Carbohydr Res; 2020 Jun; 492():107999. PubMed ID: 32272238
[TBL] [Abstract][Full Text] [Related]
8. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.
Ma Y; Kowolik CM; Swiderski PM; Kortylewski M; Yu H; Horne DA; Jove R; Caballero OL; Simpson AJ; Lee FT; Pillay V; Scott AM
ACS Chem Biol; 2011 Sep; 6(9):962-70. PubMed ID: 21766840
[TBL] [Abstract][Full Text] [Related]
9. Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.
Vankemmelbeke M; McIntosh RS; Chua JX; Kirk T; Daniels I; Patsalidou M; Moss R; Parsons T; Scott D; Harris G; Ramage JM; Spendlove I; Durrant LG
Cancer Res; 2020 Aug; 80(16):3399-3412. PubMed ID: 32532823
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.
Garrigues J; Anderson J; Hellström KE; Hellström I
J Cell Biol; 1994 Apr; 125(1):129-42. PubMed ID: 7511141
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
12. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
13. Reactivity profiles of leukemic myeloblasts with monoclonal antibodies directed to sialosyl-Le(x) and other lacto-series type 2 chain antigens:absence of reactivity with normal hematopoietic progenitor cells.
Muroi K; Suda T; Nojiri H; Ema H; Amemiya Y; Miura Y; Nakauchi H; Singhal A; Hakomori S
Blood; 1992 Feb; 79(3):713-9. PubMed ID: 1370643
[TBL] [Abstract][Full Text] [Related]
14. Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody.
Soliman C; Guy AJ; Chua JX; Vankemmelbeke M; McIntosh RS; Eastwood S; Truong VK; Elbourne A; Spendlove I; Durrant LG; Ramsland PA
Biochem J; 2020 Sep; 477(17):3219-3235. PubMed ID: 32789497
[TBL] [Abstract][Full Text] [Related]
15. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
16. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
17. Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.
Azuma A; Yamano Y; Yoshimura A; Hibino T; Nishida T; Yagita H; Okumura K; Seya T; Kannagi R; Shibuya M
Scand J Immunol; 1995 Aug; 42(2):202-8. PubMed ID: 7543216
[TBL] [Abstract][Full Text] [Related]
18. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract][Full Text] [Related]
19. Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes.
Garrigues J; Garrigues U; Hellström I; Hellström KE
Am J Pathol; 1993 Feb; 142(2):607-22. PubMed ID: 8434651
[TBL] [Abstract][Full Text] [Related]
20. Crystallization and preliminary X-ray analysis of the monoclonal anti-tumor antibody BR96 and its complex with the Lewis Y determinant.
Chang CY; Jeffrey PD; Bajorath J; Hellström I; Hellström KE; Sheriff S
J Mol Biol; 1994 Jan; 235(1):372-6. PubMed ID: 8289260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
